Shoemaker Krogh (donnatulip5)

2%). There was significant variation in airway device use between centres. The intubation rate ranged between 21% and 90% while supraglottic airway use varied between 1% and 45%. The choice of tracheal intubation vs. supraglottic airway as the second advanced airway device was not associated with immediate survival from the resuscitation attempt (odds ratio 0.81; 95% confidence interval 0.35-1.8). Conclusion There is wide variation in airway device use during resuscitation after IHCA. Only half of patients are intubated before return of spontaneous circulation and many are managed without an advanced airway. Further investigation is needed to determine optimal airway device management strategies during resuscitation following IHCA.Objectives Given the high need and the absence of specific antivirals for treatment of COVID-19 (the disease caused by severe acute respiratory syndrome-associated coronavirus-2 [SARS-CoV-2]), human immunodeficiency virus (HIV) protease inhibitors are being considered as therapeutic alternatives. Methods Prezcobix/Rezolsta is a fixed-dose combination of 800 mg of the HIV protease inhibitor darunavir (DRV) and 150 mg cobicistat, a CYP3A4 inhibitor, which is indicated in combination with other antiretroviral agents for the treatment of HIV infection. There are currently no definitive data on the safety and efficacy of DRV/cobicistat for the treatment of COVID-19. The in vitro antiviral activity of darunavir against a clinical isolate from a patient infected with SARS-CoV-2 was assessed. Results DRV showed no antiviral activity against SARS-CoV-2 at clinically relevant concentrations (EC50 > 100 μM). Remdesivir, used as a positive control, demonstrated potent antiviral activity (EC50 = 0.38 μM). Conclusions Overall, the data do not support the use of DRV for the treatment of COVID-19.Disintegration is the first event in the bioavailability cascade after the ingestion of immediate release tablets. Although the influence of various physico-chemical parameters of media on tablet disintegration has been investigated in depth, the role of temperature has received much less attention. Probing the effect of temperature on disintegration is important in order to understand if previous in vitro studies conducted at room temperature can be related to those performed at body temperature. Moreover, from a biorelevant point of view, a tablet could be co-ingested with a cold or hot drink, inducing transient variations of intragastric temperature; state of fever could also elevate body temperature. Here, we studied the effect of temperature on disintegration of directly compressed tablets made of disintegrants alone and in combination with commonly used diluents and binders, using an image analysis technique as well as a compendial disintegration apparatus. Our results indicate that temperature in the range of 23°C to 41°C had a positive effect on disintegration tablets tested at higher temperatures exhibited up to 2.9-fold faster disintegration than those tested at lower temperatures. The extent of temperature effect on disintegration time was significantly influenced by the composition of the formulations. Overall, the findings of this study suggest that disintegration results obtained in vitro at room temperature can be qualitatively, but not quantitatively, compared to those obtained at body temperature. We also speculate that although temperature had a moderate influence on in vitro disintegration, the magnitude of this effect is unlikely to impact the oral bioavailability in vivo.Recurrent outbreaks of Crimean-Congo hemorrhagic fever (CCHF) virus infection in different parts of world are a major global health concern. The CCHF viral infection is associated with severe hemorrhagic fevers and mortality up to 40%. More than 30 countries in Asia, Europe and Africa are affected with CCHF infection. Prevention of infection through vaccine becomes more important when no effective antiviral and associated therapies